# A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

> **NCT03520478** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 654 (actual)

## Conditions studied

- Prostate Cancer
- Hormone-Dependent Prostate Cancer

## Interventions

- **DRUG:** SHR3680
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT03520478
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-30
- **Primary completion:** 2023-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2021-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520478, "A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03520478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*